BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38529411)

  • 1. Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy.
    Soberanis Pina P; Lheureux S
    Biologics; 2024; 18():79-93. PubMed ID: 38529411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
    Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
    Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.
    Lheureux S; Oza AM
    Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives.
    Cuccu I; D'Oria O; Sgamba L; De Angelis E; Golia D'Augè T; Turetta C; Di Dio C; Scudo M; Bogani G; Di Donato V; Palaia I; Perniola G; Tomao F; Muzii L; Giannini A
    Healthcare (Basel); 2023 Feb; 11(4):. PubMed ID: 36833105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New concepts for an old problem: the diagnosis of endometrial hyperplasia.
    Sanderson PA; Critchley HO; Williams AR; Arends MJ; Saunders PT
    Hum Reprod Update; 2017 Mar; 23(2):232-254. PubMed ID: 27920066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
    Westin SN; Moore K; Chon HS; Lee JY; Thomes Pepin J; Sundborg M; Shai A; de la Garza J; Nishio S; Gold MA; Wang K; McIntyre K; Tillmanns TD; Blank SV; Liu JH; McCollum M; Contreras Mejia F; Nishikawa T; Pennington K; Novak Z; De Melo AC; Sehouli J; Klasa-Mazurkiewicz D; Papadimitriou C; Gil-Martin M; Brasiuniene B; Donnelly C; Del Rosario PM; Liu X; Van Nieuwenhuysen E;
    J Clin Oncol; 2024 Jan; 42(3):283-299. PubMed ID: 37864337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
    Whelan K; Dillon M; Strickland KC; Pothuri B; Bae-Jump V; Borden LE; Thaker PH; Haight P; Arend RC; Ko E; Jackson AL; Corr BR; Ayoola-Adeola M; Wright JD; Podwika S; Smitherman C; Thomas S; Lightfoot M; Newton M; Washington C; Mullen M; Cosgrove C; Harsono AAH; Powell K; Herzog TJ; Salani R; Alvarez Secord A
    Gynecol Oncol; 2023 Nov; 178():44-53. PubMed ID: 37748270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
    Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
    J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.
    Weigelt B; Marra A; Selenica P; Rios-Doria E; Momeni-Boroujeni A; Berger MF; Arora K; Nemirovsky D; Iasonos A; Chakravarty D; Abu-Rustum NR; Da Cruz Paula A; Dessources K; Ellenson LH; Liu YL; Aghajanian C; Brown CL
    Cancer Discov; 2023 Nov; 13(11):2356-2369. PubMed ID: 37651310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FIGO staging of endometrial cancer: 2023.
    Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
    Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
    Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
    Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.